

DUODART

(dutasteride/tamsulosin HCl) Capsules



Relief and prevention go hand in hand in men with moderate to severe LUTS / BPH at risk of progression¹

DUAL ACTION²:

- ⚡ Superior symptoms improvement[^]
- ↓ Superior prostate size reduction^{*}

vs tamsulosin monotherapy

DUAL PROTECTION²:

Reduce relative risk of

- AUR by **68%**
- BPH related surgery by **71%**

vs tamsulosin monotherapy

Safety information on Duodart¹:

Adverse events associated with Duodart include impotence, decreased libido, ejaculation disorders, breast tenderness and enlargement, and dizziness. Men taking Duodart should be regularly evaluated for prostate cancer risk including PSA testing. Any confirmed increase from lowest PSA level while on Duodart may signal the presence of prostate cancer or noncompliance to therapy with Duodart and should be carefully evaluated. Duodart is contraindicated in women, children; patients with hypersensitivity to 5-alpha reductase inhibitors, tamsulosin or any of the excipients; patients with history of orthostatic hypotension; patients with severe hepatic impairment or severe renal impairment.

For reporting of adverse events please write to sg.drugsafety@gsk.com
All images used in this material are for illustration purposes only
Full Prescribing Information is available on request. Please [click](#) here for Full Prescribing Information.

Please read the full prescribing information prior to administration, available from
GlaxoSmithKline Pte Ltd, 23 Rochester Park, Singapore 139234. Tel: +65 62328338.

PM-SG-DTT-ADVT-200001 Certified June 2020

For Singapore Healthcare Professionals Only
©2020 GSK group of companies or its licensor
Trademarks are owned by or licensed to the GSK group of companies

AUR: Acute Urinary Retention; BPH: Benign Prostatic Hyperplasia; LUTS: Lower Urinary Tract Symptoms.

[^] The adjusted mean change in IPSS from baseline to year 4 was **-6.3** points for combination therapy vs. **-3.8** points for tamsulosin. ^{*} The adjusted mean change from baseline to year 4 in total prostate volume was **-27.3%** for combination therapy vs. **+4.6%** for tamsulosin.

References:

1. Duodart Singapore Prescribing Information (IPI12SI). 2. Roehrborn CG, et al. *Eur Urol* 2010;57(1):123-31.